Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016972 | 0.81 | P2RX7 (0.52) | P2RX7KCNQ2HDAC4HDAC7HDAC5 | |
| SCHEMBL28623508 | 0.80 | MAPT (0.48) | — | |
| SCHEMBL26534229 | 0.77 | ACKR3 (0.53) | P2RX7FFAR2KCNQ2HDAC4HDAC7 | |
| SCHEMBL13979540 | 0.74 | P2RX7 (0.45) | P2RX7HDAC4HDAC7HDAC5 | |
| SCHEMBL3136218 | 0.74 | P2RX7 (0.46) | P2RX7HDAC4HDAC7HDAC5POLB | |
| SCHEMBL13761340 | 0.73 | PRMT5 (0.46) | RECQLF2POLBACKR3 | |
| SCHEMBL14014153 | 0.73 | NPC1 (0.54) | P2RX7POLBACKR3 | |
| SCHEMBL4707323 | 0.73 | TSHR (0.41) | HDAC4HDAC7HDAC5RECQLF2 | |
| SCHEMBL29559032 | 0.72 | ALDH1A1 (0.53) | P2RX7HDAC4HDAC7HDAC5TSHR | |
| SCHEMBL2083786 | 0.72 | ALDH1A1 (0.53) | P2RX7HDAC4HDAC7HDAC5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | P2RX7 1667/4885FFAR2 1485/4885PSMB5 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.